(Date:11/24/2009)... , , SAN MATEO, Calif., Nov. 24 /PRNe...X ), a biopharmaceutical company focused on develo...rapies, announced today that Anthony DiTonno, Pres... present at the 21st Annual Piper Jaffray Health C...he New York Palace Hotel in New York, New York. ,...
(Date:11/24/2009)... , , , Primary efficacy endpoint has ...ecurrent endometrial cancer, , QUEBEC CITY, N...nc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a ...ine therapy and oncology, today announced positive...ted cytotoxic peptide conjugate, AEZS-108 (formerl...
(Date:11/24/2009)... , , REDWOOD CITY, Calif., Nov. 24 /PRN...: GHDX ) today announced that Randy Scott, Genomi... 21st Annual Piper Jaffray Health Care Conference ...0:00 a.m. ET. ,, To access the live and subseq... the Investor Relations section of Genomic Health,...
(Date:11/24/2009)... , , SEATTLE, Nov. 24 /PRNewswire-Fir...nd MTA: CTIC) management will present at the 21st ...onference will be held December 1-2, 2009, at the ... Tuesday, December 1 at 11:00 a.m. Eastern Time in...,s presentation will be available at www.cellther...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2